ArticleProceedings of the National Academy of Sciences of the United States of America2017
Lysibodies are IgG Fc fusions with lysin binding domains targeting
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- LYSG101: a potent chimeric lysin with therapeutic potential for combatingAntimicrobial agents and chemotherapy · 2026Article
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Key directions of fundamental research on bacteriophage Receptor Binding Proteins with applied potential.Frontiers in microbiology · 2026Review
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- Evaluation of Heparin-Binding Protein as a novel biomarker for the detection of periprosthetic joint infection.Frontiers in cellular and infection microbiology · 2025Article
- Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Staphylococcus aureus cell wall maintenance - the multifaceted roles of peptidoglycan hydrolases in bacterial growth, fitness, and virulence.FEMS microbiology reviews · 2022Review
- An Engineered Multimodular Enzybiotic against Methicillin-ResistantLife (Basel, Switzerland) · 2021Article
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- Methicillin-Resistant Staphylococcus aureus in Hospitals: Latest Trends and Treatments Based on Bacteriophages.Journal of clinical microbiology · 2019Review
- Targets of immunomodulation in bacterial endophthalmitis.Progress in retinal and eye research · 2019Review
- Article
- Lysostaphin Lysibody Leads to Effective Opsonization and Killing of Methicillin-Resistant Staphylococcus aureus in a Murine Model.Antimicrobial agents and chemotherapy · 2018Article
- Article
- Antibody-Based Agents in the Management of Antibiotic-Resistant Staphylococcus aureus Diseases.Microorganisms · 2018Review
- Infection therapy: the problem of drug resistance - and possible solutions.Microbial biotechnology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cell wall of Gram-positive bacteria contains abundant surface-exposed carbohydrate molecules that are highly conserved within and often across species. The potential therapeutic usefulness of high-affinity antibodies to cell wall carbohydrates is unquestioned, however obtaining such antibodies is challenging due to the poor overall immunogenicity of these bacterial targets. Autolysins and phage lysins are peptidoglycan hydrolases, enzymes that have evolved over a billion years to degrade bacterial cell wall. Such wall hydrolases are modular enzymes, composed of discrete domains for high-affinity binding to cell wall carbohydrates and cleavage activity. In this study, we demonstrate that binding domains from autolysins and lysins can be fused to the Fc region of human IgG, creating a fully functional homodimer (or "lysibody") with high-affinity binding and specificity for carbohydrate determinants on the bacterial surface. Furthermore, we demonstrate that this process is reproducible with three different binding domains specific to methicillin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.